南美锥虫病：美国锥虫病市场

本报告调查了全球南美锥虫病市场，并提供了市场概况、市场影响因素分析、市场规模趋势和预测、各个细分市场和地区的详细分析、新药趋势、竞争形势以及主要企业。.进行了总结。

目录

第一章简介

第 2 章摘要/亮点

第三章市场概况

• 历史
• 克氏锥虫
• 向量和 T. cruzi
• 感染途径
• 疾病类型
• 前景
• 新药

第 4 章南美锥虫病：透过药物

• 概述
• 苯并硝唑
• 苯并硝唑毒性
• 硝呋替莫
• 硝呋莫司毒性

第 5 章南美锥虫病：诊断

• 概述
• 血清学（抗体检测）
• 分子检测

第六章 竞争形势

• 竞争分析

第七章 公司简介

• BAYER AG
• INSUD PHARMA

第 8 章附录：首字母缩写词

Highlights:

The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.

Report Scope:

The current research provides a thorough overview of the CD market. This report analyzes CD market trends with epidemiological and regional markets, highlights the current market and offers a detailed competitive environment analysis. The scope of this report covers treatment throughout Latin America.

Report Includes:

• An overview of the global chagas disease (T. cruzi infection) market
• Analyses of the global market trends, with historical market revenue from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
• Estimate of the market size and revenue forecast for global chagas disease market, and corresponding market share analysis based on the product type, treatment, and region
• Overview of the significant driving trends and challenges that affect the global market and its vendor landscape
• Review of the epidemiology of chagas disease and potential of key marketed drugs and recent approvals
• Discussion of sustainability trends and factors in the chagas disease market, with emphasis on consumer attitudes, ESG score analysis, future of ESG, case study, and the ESG practices followed
• Analysis of the competitive intelligence based on recent developments, key financials and segmental revenues, and product launch strategies
• Detailed profiles of leading market participants, providing a descriptive overview of their respective businesses

Table of Contents

Chapter 1 Introduction

• Overview
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Information Sources
• Segmentation Breakdown

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

• History
• Trypanosoma Cruzi
• Vector and T. cruzi
• Transmission Routes
• Clinical Forms
• Future Perspectives
• Novel Drugs

Chapter 4 Chagas Disease by Drugs

• Overview
• Benznidazole
• Toxicity of Benznidazole
• Nifurtimox
• Toxicity of Nifurtimox

Chapter 5 Chagas Disease by Diagnosis

• Overview
• Serology (Antibody Detection)
• Molecular Testing

Chapter 6 Competitive Landscape

• Competitive Analysis

Chapter 7 Company Profiles

• BAYER AG
• INSUD PHARMA

Chapter 8 Appendix: Acronyms

List of Tables

• Table 1 : Novel Drugs for Chagas Disease Treatment
• Table 2 : Drugs for Chagas Disease
• Table 3 : Bayer AG: Company Snapshot
• Table 4 : Bayer AG: Annual Revenue, 2021 and 2022
• Table 5 : Bayer AG: News
• Table 6 : Insud Pharma: Company Snapshot
• Table 7 : Insud Pharma: News
• Table 8 : Acronyms Used in This Report

List of Figures

• Summary Figure : Life Cycle of Trypanosoma Cruzi
• Figure 1 : Bayer AG: Annual Revenue, 2021 and 2022
• Figure 2 : Bayer AG: Revenue Shares, by Business Unit, 2022
• Figure 3 : Bayer AG: Revenue Shares, by Region, 2022